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ABStRAct
Objective: To report on preliminary outcomes of single-dose intraoperative 
radiotherapy for early-stage breast cancer based on local recurrence 
rates and complications. Methods: Fifty postmenopausal women 
with ≤2.5cm breast tumors and clinically normal axillary lymph nodes 
were submitted to quadrantectomy, sentinel lymph node biopsy and 
intraoperative radiotherapy and studied. Mean follow-up time was 
52.1 months. Results: Mean patient age was 65.5 years; mean tumor 
diameter was 1.41cm 82% of nodules were hormonal receptor positive 
and HER-2negative. All patients received a 21 Gy radiation dose for a 
mean time of 8.97 minutes. Distant metastases were not observed. 
Local recurrence was documented in three cases, with identical 
histological diagnosis as the primary tumors. Thirty-five (70%) patients 
had local fibrosis, with gradual improvement and complete resolution 
over 18 months. Postoperative infection and seroma formation were 
not observed. conclusion: Partial radiotherapy is a potentially feasible 
and promising technique. Careful patient selection is recommended 
before a longer follow-up period has elapsed to confirm intraoperative 
radiotherapy safety and efficacy. 
Keywords: Breast neoplasms/surgery; Breast neoplasms/radiotherapy; 
Radiotherapy/methods; Antineoplastic protocols
ReSUMO
Objetivo: Avaliar a experiência inicial de implementação e aplicação 
de radioterapia única e intraoperatória com feixe de elétrons em 
pacientes selecionadas com diagnóstico de câncer de mama em 
estágio inicial. Avaliar também a recorrência local e os eventos 
adversos (complicações locais). Métodos: Foram avaliadas 50 
pacientes com câncer de mama, pós-menopausadas, com tumores 
de ≤2,5cm e linfonodos axilares clinicamente não palpáveis, que 
se submeteram a uma ressecção segmentar e biópsia de linfonodo 
sentinela e técnica de radioterapia intraoperatória. Essas pacientes 
foram seguidas por um período médio de 52,1 meses. Resultados: 
A idade média dos pacientes foi de 65,5 anos de idade. O diâmetro 
médio do tumor foi de 1,41cm 82% tinham tumores com receptor 
hormonal positivo e HER-2 negativo. A dose de radiação empregada 
foi de 21 Gy em todas as pacientes, com um tempo médio de 
irradiação intraoperatória de 8,97 minutos. O seguimento médio 
dessas pacientes foi de 52,1 meses. Foram evidenciados três casos 
com recorrência local durante esse período, sendo que nenhuma 
dessas pacientes tinha metástases à distância no momento do 
diagnóstico da recidiva. O diagnóstico patológico dessas três pacientes 
foi idêntico ao do tumor primário. Nesta casuística, não se registrou 
infecção pós-operatória ou formação de seroma. No entanto, em 
35 pacientes (70%), foi observada uma fibrose local como sequela 
de pós-operatório. Esta, quando presente, diminuiu gradualmente e 
desapareceu completamente em um período médio de 18 meses. 
conclusão: A radioterapia parcial é uma técnica viável e promissora, 
mas que deve ser indicada em casos selecionados, pelo menos até 
que tenhamos um maior tempo de seguimento que proporcione 
maior segurança para indicá-la em nossa rotina, como fazemos com 
a radioterapia convencional.
Descritores: Neoplasias da mama/cirurgia; Neoplasias da mama/
radioterapia; Radioterapia/métodos; Protocolos antineoplásicos 
INtRODUctION
Breast cancer is a global problem accounting for 10.4% 
of malignant neoplasms in women. Breast cancer is also 
the fifth leading cause of cancer death(1).  
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According to data from Incidência de Câncer no 
Brasil 2012 (Instituto Nacional do Câncer - INCA; HTTP://
www1.inca.gov.br/estimativa/2012/), an estimated 50 new 
breast cancer cases will be diagnosed in 2012. High 
national breast cancer incidence rates have encouraged 
the implementation of cancer screening programs for 
earlier breast cancer diagnosis.
Early-stage breast cancers should be treated with 
breast-conserving surgery, total or selective (sentinel) 
axillary lymph node assessment and adjuvant external-
beam radiotherapy (EBRT) for improved local-regional 
control and global survival rates(2,3).
Several independent factors, such as patient age, 
tumor size, peritumoral vascular invasion, tumor histologic 
subtype and intracanalicular extension are known to 
be directly related to cancer recurrence. However, 
radiotherapy is paramount to decrease local recurrence 
rates(3). Similar global survival rates have been reported 
following mastectomy or breast-conserving surgery followed 
by EBRT(4-20).
The initial hypothesis that wide segmental resection 
might eliminate the need for EBRT in selected cases was 
not supported by the outcomes of the B-21trial (National 
Surgical Adjuvant Breast and Bowel Project - NSABP)(9), 
which have stressed the relevance of EBRT for decreased 
recurrence rates. The benefits of adjuvant EBRT to local 
control and complete breast cancer resolution have 
been confirmed in randomized studies comparing the 
outcomes of breast conserving surgery with and without 
EBRT(7,10-21). According to the National Institutes of 
Health (NIH, http://www.nih.gov/), breast-conserving 
surgery followed by EBRT is the current treatment of 
choice for early-stage breast cancer(10). Sadly, despite 
widely reported benefits, compliance with adjuvant 
radiotherapy is not always achieved due to geographical 
(e.g. distance from large cities), socioeconomic and 
personal constraints (e.g. elderly patients requiring 
support from a caregiver). Also, several countries lack 
the infrastructure (e.g. radiotherapy equipment) required 
to meet domestic population demands(11-13).
In this scenario, partial breast irradiation seems 
to be a potentially feasible and practical option. 
Intraoperative radiotherapy (IORT) with electrons 
is a partial radiotherapy technique delivering a single 
radiation dose directly to the tumor bed following 
quadrantectomy, segmental resection or tumorectomy, 
with similar biological effectiveness to standard EBRT.
OBJectIVe
To report on the preliminary outcomes of breast-conserving 
surgery followed by IORT in early-stage breast cancer.
MetHODS
This project was approved by the Research Ethics 
Committee of Hospital Israelita Albert Einstein – HIAE 
(CEP/Einstein number 04/87). Fifty patients were 
selected out of 104 patients recruited at the HIAE 
between June 2004 and July 2010. Eligibility criteria 
were surgical or natural menopause (no menses for 
more than one year); no previous or concurrent breast 
cancer treatment; histologic diagnosis of invasive ductal, 
medullary, colloid (mucinous) or tubular carcinoma 
without extensive intraductal component and with 
negative margins upon intraoperative assessment; cancer 
lesions≤2.5cm in diameter); unilateral breast tumors 
with no signs of multicentricity or multifocality upon 
clinical examination, ultrasonography, mammogram and 
magnetic resonance imaging (MRI) and no previous 
neoplasm except non-melanoma skin tumors. 
Exclusion criteria were as follows: Patients suffering 
from ductal in situ, lobular in situ, Paget or inflammatory 
carcinoma; patients diagnosed with multicentric/multifocal 
disease based on imaging methods; patients with 
metastatic tumors at different locations; patients with 
active collagen disease (particularly systemic lupus 
erythematosus, scleroderma or dermatomyositis) and 
comorbidities associated with ≤2 years life expectancy.
Pre-and intraoperative assessment was based on 
complete clinical history, including family history 
and tumor detection methods (physical examination, 
mammogram, ultrasonography and MRI), complete 
clinical staging (thoracic radiography, abdominal 
ultrasonography, bone scintigraphy and tumoral markers) 
and post-operative radiography confirming complete 
elimination of pre-existing microcalcifications when 
applicable. 
All patients agreed to comply with the treatment plan 
as discussed with the multidisciplinary team. Informed 
consent was given in all cases. Patients were operated at 
the HIAE Radiotherapy Department operating room, 
next to the room where the linear accelerator employed 
in this study is located.
Segmental resection was performed under general 
anesthesia in compliance with surgical oncology guidelines 
(e.g. en bloc tumor resection with broad healthy tissue 
margins, including deep fascia and skin as necessary). 
Tumor specimens were submitted to intraoperative 
histological grading. Unicentricity and surgical margin 
width were also determined.
Intraoperative histological assessment was performed 
to confirm the presurgical diagnosis. Surgical margins were 
marked with china ink to facilitate the determination of 
margin width. Margins were either curetted for cytology 
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or biopsied (lesions >5mm in size). Biopsy specimens 
were cut at 4-5mm intervals and evaluated to confirm 
negative margins (>2mm)(14,15). Additional tissue resection 
was requested to achieve negative margins as necessary. 
Lymphadenectomy was performed using the sentinel 
lymph node method or standard axillary lymph node 
dissection.
Glandular flaps were mobilized off the subcutaneous 
tissue and temporarily approximated with sutures to 
allow IORT to be delivered. The thoracic wall was 
shielded with a 3mm aluminum-lead disk or similar 
device to minimize backscattering. Patients were then 
taken to the adjacent room under general anesthesia 
and positioned for IORT to achieve alignment between 
the collimator and the electron beam. Patients were 
assisted by multidisciplinary team members at all 
times. 
Following separation of the skin using a dedicated 
positioning system, the target area was demarcated 
using special ink (skin marking pen). A single radiation 
dose was delivered to the glandular area adjacent to the 
resected quadrant using a linear particle accelerator 
(LINAC). Electron energy levels ranged from 6 to 12 
Mev according to individual target gland thickness. 
A full 21Gy dose was delivered using IORT cones 
and collimators large enough to include wide surgical 
margins. Energy settings and internal cone diameter 
and position were determined at the discretion of the 
medical team (Figures 1 and 2). 
IORT was delivered exclusively by radiotherapy 
team members according to recommendations by Veronesi 
et al.(16). Previous specific training was provided to the 
nursery team.
Intra and post-operative histopathological assessment 
of tumor diameter, tumor histological grade, sentinel 
and axillary lymph nodes and surgical margins were 
performed. Tumor histological grade and peritumoral 
vascular invasion were based on criteria proposed 
by Elston and Ellis(17) and Rosen et al.(18) respectively. 
Estrogen (ER) and progesterone (PR) receptor status and 
Human Epidermal growth factor receptor 2 (HER-2) 
expression were determined using immunohistochemistry. 
Fluorescence in situ hybridization (FISH)(19) test was 
employed when necessary. 
Hormone therapy with or without combined 
chemotherapy was recommended based on detailed 
tumor histology investigation and multidisciplinary case 
discussion.
Patients with local tumor recurrence were submitted 
to a second segmental resection or radical mastectomy. 
Adjuvant therapy was prescribed based on previous 
treatment outcomes following multidisciplinary case 
discussion.
Patients were seen by at least one member of the 
medical team every 3, 4 and 6 months in the first, 
second and third to fifth follow-up year respectively, 
and yearly thereafter. Clinical data were thus updated 
on physicians and radiotherapy records. Mean follow-
up time was 52.1 months (median, 54.2 months). All 
complications were treatment related and consisted 
of fat necrosis, fibrosis, retraction, deformity or other 
radiation- dependent events.
ReSULtS
All patients were submitted to adjuvant hormone therapy. 
Abnormal histopathologic findings (hematoxylin-eosin 
Figure 1. Intraoperative radiotherapy – the collimator (purple) is connected to the 
linear accelerator and positioned into the mammary gland following elevation of 
the skin overlying the tumor
Figure 2. Mammary tissue circumjacent to the tumoral bed following temporary 
apposition. The target area as defined by the collimator is displayed 
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staining and immunohistochemistry) following single-
dose IORT were recognized in 7 patients and treated 
either with chemotherapy or trastuzumab (5 and 2 cases 
respectively).
All patients studied were submitted to breast-
conserving surgery and single-dose IORT. Tumor-free 
surgical margins were confirmed intraoperatively in all 
cases. Narrow margins (0.1-0.2mm) were documented 
in 2 (4%) cases. Affected patients were not reoperated.
Sentinel lymph node investigation was performed 
in all cases; 2 lymph nodes were removed per surgery 
on average. Level I and II axillary dissection was 
performed in 3 patients (6%; 17 lymph nodes removed 
on average) following recognition of a compromised 
sentinel lymph node. The sentinel node was confirmed 
to be the only compromised lymph node in all cases, 
with compromised areas of less than 2mm. 
A single 21 Gy dose of electrons was administered 
to all patients. Energy levels of 6 MeV and 9 Mev 
were employed in 27 (54%) and 23 (46%) of patients 
respectively. Internal cone diameter ranged from 5 to 
9cm. Isodose curves (%) were adjusted according to 
individual gland thickness (Table 1). 
Complications such as post-operative infection, 
seroma accumulation requiring drainage following 
suction drain removal, hematomas, wound dehiscence 
and radiotherapy toxicity were not observed in this 
study. Local post-operative fibrosis occurred in 35 (70%) 
patients, with gradual improvement or total resolution 
over 18 months. Complete fibrosis resolution in less 
than 12 months was documented in 20 (57.1%) affected 
patients. Mild skin retraction was observed in 3 (6%) 
cases. Steatonecrosis without associated clinical signs 
but evident on palpation and imaging was diagnosed in 
5 (10%) patients.
Local recurrence was documented in 3 (6%) patients. 
Case review revealed tumor-free margins, negative 
vascular invasion and absence of axillary compromise. 
Two patients (aged 55 and 61 years respectively) had 
positive HER-2, ER and PR status and intraparenchymal 
recurrence at or adjacent to the operated quadrant. The 
third patient (aged 49 years) had negative HER-2 and 
positive RE and PR status and recurrence in the surgical 
scar (non-irradiated area). Histopathologic diagnosis 
was the same as the primary tumor in all cases.
Local recurrence cases were retreated. Patients with 
intraparenchymal recurrence were submitted to radical 
mastectomy and myocutaneous flap reconstruction. 
The third patient (scar recurrence) was submitted to a 
second local resection followed by EBRT (50 Gy). All 
patients progressed well, with no signs of local or distant 
disease to the time of publication. Distant metastases 
were not documented and disease-free survival to date 
was achieved in all cases studied. 
DIScUSION
Whole-breast EBRT following segmental breast resection 
is thought to reduce local recurrence rates due to the 
elimination of local and remote residual neoplasm. 
This hypothesis is supported by reports of Rosen 
et al.(18) and Holland et al.(22) on 203 mastectomy 
specimens: multicentric invasive or in situ neoplasm 
was recognized in 26% specimens with lesions ≤2cm 
and 36% specimens with lesions measuring between 
2.1 and 4cm. However, the biological significance of 
occult neoplasm and the role of EBRT remain to be 
determined. 
In a meta-analysis (Early Breast Cancer Trialists’ 
Collaborative Group – EBCTCG, 2011) of 17 trials 
involving 10,081 women with early-stage breast cancer 
submitted to breast-conserving surgery followed by 
EBRT, conventional radiotherapy was shown to decrease 
absolute recurrence rates in patients with negative or 
positive lymph nodes, and to improve survival rates(3).
The idea of using focal irradiation with partial 
preservation of the mammary gland was based on 
local recurrence rate patterns reported in the Milan 
table 1. Clinical and radiotherapeuthic data from 50 early-stage breast cancer cases submitted to intraoperative radiotherapy
Variables Mean Median Standard deviation Minimum Maximum
Age (years) 65.1 64.0 10.6 45.0 84.0
Tumor diameter (cm) 1.41 1.45 0.54 0.50 2.50
Radiotherapy time (min) 8.97 8.66 1.23 6.88 11.85
Depth (cm) 1.90 1.95 0.46 0.90 3.00
Cone (cm) 4.96 5.10 0.52 4.50 6.40
Isodose curve (%) 97.0 100.0 4.81 85.0 100.0
Follow-up (years) 4.83 4.83 1.60 1.18 7.35
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III trial(4). In that trial, breast tumors measuring 
less than 2.5cm treated either with quadrantectomy 
or quadrantectomy and post-surgical EBRT were 
compared. Reported local recurrence rates (median 
follow-up period, 119 months) were 21.6% and 5.4% 
in non-irradiated and irradiated patients respectively 
(p=0.001). 
Locally recurrent lesions following segmental resection 
and EBRT tend be histologically similar and affect 
the same site as the primary tumor in 65 to 100% of 
cases, suggesting the persistence of residual neoplasm 
in non-irradiated tissues around the operated area(4,23). 
If local tumor recurrence rates following breast-
conserving surgery with negative margins and adjunct 
EBRT are to be expected in approximately 10% of 
cases, it could be argued that only 0 to 3.5% of these 
patients will experience tumor recurrence outside 
the primary site, a percentage well below the expected 
incidence of multicentricity reported by Rosen and 
Holland(18,24). 
Several studies investigating the benefits of partial 
irradiation, respective impacts on breast cancer resolution 
and applicability in different communities have been 
published. Different partial radiotherapy techniques 
are currently being studied with promising, albeit 
controversial results(16,25).
In some studies, conventional EBRT has been shown 
to be associated with lower (10%) recurrence rates when 
compared to partial irradiation (19.5%). However, the 
opposite outcome was reported in others (e.g. non-
randomized study by Reitsamer et al.)(26,27).
Intrabeam IORT (a low energy photon beam focused 
on a specific target area) provides low irradiation energy 
and is currently being used in the United States, United 
Kingdom, Germany, Australia and Italy. The first 
analysis (TARGIT trial)(25) concerning this treatment 
modality was published in June 2010 and compared 
the effects of single-dose IORT and EBRT following 
breast-conserving surgery in early-stage breast cancer. 
Recurrence and clinically significant toxicity rates of 
1% and 3% respectively were reported after a 4-year 
follow-up(25).
According to the American Society for Therapeutic 
Radiation Oncology (ASTRO), partial breast radiotherapy 
is a novel technology for application in selected patients. 
The superiority of this technique over conventional EBRT 
in treatment of early-stage breast cancer from a efficacy 
and safety standpoint remains to be etermined(28). 
The IORT modality employed in this study 
protects the skin from the effects of radiation and 
enables patients to resume their customary routine 
activities immediately after recovery from surgery, 
with less impact on patient personal life. The risk of 
delayed irradiation due to adjuvant chemotherapy is 
eliminated and the irradiation of adjacent organs such 
as the lungs and the contralateral mammary gland is 
also avoided. 
The irradiation method employed in this study was 
described by Veronesi et al.(16). Ideal radiation dose, 
applicability, reproducibility and efficacy of the method 
were investigated in phase I, II and III trials involving 
1,822 patients analyzed between 2000 and 2008. Fibrosis 
without cosmetic disfigurementand liponecrosis were 
reported in 1.8% and 4.8% of cases, respectively(16). In 
this study, high local fibrosis rates were documented 
(70% of patients), with regression over approximately 
12 months in 57.1% of cases. Local fibrosis with skin 
retraction (3 cases; 6%) was the most severe esthetic 
complication in the cases studied and was graded 
unimportant by affected patients. Cosmetic repair was 
therefore not performed.
Contrasting with recurrence rates of 2.3% over 
36 months reported by Veronesi et al.(16), a 6% local 
recurrence rate was documented during the first 42 
months following IORT in this study.
Average local recurrence rates of 6.7% have been 
documented in the first 5 years following breast-
conserving surgery and EBRT in patients with negative 
axillary lymph nodes(2,3). A 15.4% decrease in the absolute 
local recurrence risk (relative risk, 0.46; 95% confidence 
interval, 0.41-0.51) has been reported by the ABCTCG 
in a 10-year follow-up of patients with tumor-free 
axillary lymph nodes(3). 
The high local recurrence rates in this study do 
not support the efficacy of the treatment modality 
employed. Despite the low number of patients studied, 
the importance of strict inclusion criteria and careful 
patient selection cannot be overemphasized. ASTRO 
eligibility criteria should be adopted: age ≥60 years, 
T1 stage, absence of extensive ductal carcinoma in situ, 
negative axillary lymph nodes, ER positive tumors, 
negative lymphovascular invasion, minimum tumor-
free margin width of 2mm and absence of multicentric 
disease(29).
Despite the above considerations, the fact that all 
patients studied are alive, without evidences of local or 
distant disease to the time of publication is encouraging. 
At this time, IORT should be employed for investigation 
purposes only. Randomized trials 0413 (Radiation 
Therapy Oncology Group; RTOG), B-39 (NSABP) 
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and IMPORT LOW (United Kingdom) are expected 
to clarify IORT indication criteria and efficacy in the 
near future.  
cONcLUSION
Partial radiotherapy is a feasible and promising technique. 
However, at this stage strict compliance with ASTRO 
criteria is recommended and only carefully selected 
patients should be treated. A longer follow-up period 
is required before IORT can be considered as safe as 
conventional radiotherapy.
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